CT
Celea TherapeuticsClinical-stage biotech developing deupirfenidone, a deuterated pirfenidone-derived drug for idiopathic pulmonary fibrosis, spun out of PureTech Health.
4 Pulse stories
JN
Jupiter NeurosciencesClinical-stage biotech developing JOTROL, a proprietary high-bioavailability resveratrol platform targeting neuroinflammation, mitochondrial dysfunction, and longevity indications including Parkinson's and Alzheimer's disease.
1 Pulse story
Total Raised
$180M
Celea TherapeuticsJupiter Neurosciences
Last ValuationNot disclosed
Biotech
Sector
Biotech
2025
Founded
—
Boston, MA
HQ
Jupiter, Florida
Private
Status
Public (JUNS)
Celea Therapeutics investors
RA Capital ManagementLeaps by BayerPureTech Health
Jupiter Neurosciences investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Celea Therapeutics and Jupiter Neurosciences.